

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **June 1, 2010**

Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-33137
(Commission
File Number)

14-1902018
(IRS Employer
Identification No.)

2273 Research Boulevard, Suite 400, Rockville, Maryland
(Address of Principal Executive Offices)

20850
(Zip Code)

Registrant's telephone number, including area code: **(301) 795-1800**

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 1, 2010, the Board of Directors (the "Board") of Emergent BioSolutions Inc. (the "Company") appointed Marvin White as a Class II director. Mr. White is an independent director within the meaning of the rules of the New York Stock Exchange. Mr. White will stand for election with the other Class II directors at the Company's 2011 annual meeting of stockholders.

Mr. White is currently system vice president and chief financial officer of St. Vincent Health. Prior to joining St. Vincent Health in 2008, Mr. White was executive director and chief financial officer of LillyUSA, a subsidiary of Eli Lilly and Company, where he also held leadership positions in Corporate Finance and Investment Banking in the Corporate Strategy Group. He serves on the boards of Marian University, Advantage Health Solutions, Inc., and has been active with the Center for Leadership Development, Saving Orphans through Healthcare and Outreach (SOHO) and with the United Way. Mr. White earned his bachelor's in Accounting from Wilberforce University, and master's of Business Administration in Finance from Indiana University.

There is no arrangement or understanding pursuant to which Mr. White was appointed as a director and there are no related party transactions between the Company and Mr. White.

On June 4, 2010, the Company issued a news release on Mr. White's appointment to the Board, which is furnished as Exhibit 99.1 and is attached to this Form 8-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 4, 2010

EMERGENT BIOSOLUTIONS INC.

By: /s/ R. Don Elsey

R. Don Elsey

Chief Financial Officer

Exhibit List

99.1 Press Release dated June 4, 2010

FOR IMMEDIATE RELEASE

Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com

Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com

EMERGENT BIOSOLUTIONS ANNOUNCES APPOINTMENT OF MARVIN WHITE TO THE COMPANY'S BOARD OF DIRECTORS

ROCKVILLE, MD, June 4, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company's Board of Directors appointed Marvin White as a Class II Director for a one-year term that will expire at the 2011 annual meeting of stockholders.

"Mr. White's expertise in financial management, gained in a patient-focused health care system and service-oriented environment, will prove an invaluable asset in guiding Emergent's management team towards further growth and in increasing value for shareholders," said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. "We are delighted to welcome him to Emergent's Board of Directors, composed of seasoned experts with diverse skill sets."

"It is an honor to serve on the Board of a company whose mission is to protect life by providing and developing life-saving vaccines and treatments that benefit public health," said Mr. White. "Through this opportunity, I look forward to contributing to Emergent's success by drawing from my experience in health care systems and pharmaceuticals as well as my efforts in philanthropy."

Mr. White is currently system vice president and chief financial officer of St. Vincent Health, one of the largest and most comprehensive health care systems in Indiana. His responsibilities include finance, materials management, accounting, patient financial services, and managed care for all 19 St. Vincent Health ministries, as well as 36 joint ventures. St. Vincent Health is dedicated to spiritually-centered, holistic care that sustains and improves the health of individuals and communities.

Prior to joining St. Vincent Health in 2008, Mr. White was executive director and chief financial officer of LillyUSA, a subsidiary of Eli Lilly and Company, where he also held leadership positions in Corporate Finance and Investment Banking in the Corporate Strategy Group. He serves on the boards of Marian University, Advantage Health Solutions, Inc., and has been active with the Center for Leadership Development, Saving Orphans through Healthcare and Outreach (SOHO) and with the United Way. Mr. White earned his bachelor's in Accounting from Wilberforce University, and master's of Business Administration in Finance from Indiana University.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent's product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

###